Home Markets Lilly’s next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trial

Lilly’s next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trial

Andrew M Dec 11, 2025 comments off

Original source: https://www.investing.com/news/stock-market-news/lillys-nextgen-drug-tops-zepbound-on-weight-loss-in-latestage-osteoarthritis-trial-4403032

late-stage osteoarthritis Market Updates nextgen www.investing.com/news/stock-market-news/lillys-nextgen-drug-tops-zepbound-on-weight-loss-in-latestage-osteoarthritis-trial-4403032